AI assistant
DEXCOM INC — Director's Dealing 2021
Mar 11, 2021
30198_dirs_2021-03-10_6d0e1985-27f7-4f78-b5d8-b30a2fe7489c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2021-03-08
Reporting Person: Sylvain Jereme M (SVP, Finance & CAO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-08 | Common Stock | A | 5301 | $0.001 | Acquired | 16049 | Direct |
Footnotes
F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021.